1. Home
  2. GKOS vs NEA Comparison

GKOS vs NEA Comparison

Compare GKOS & NEA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • GKOS
  • NEA
  • Stock Information
  • Founded
  • GKOS 1998
  • NEA 2002
  • Country
  • GKOS United States
  • NEA United States
  • Employees
  • GKOS N/A
  • NEA N/A
  • Industry
  • GKOS Medical/Dental Instruments
  • NEA Finance/Investors Services
  • Sector
  • GKOS Health Care
  • NEA Finance
  • Exchange
  • GKOS Nasdaq
  • NEA Nasdaq
  • Market Cap
  • GKOS 5.4B
  • NEA 3.4B
  • IPO Year
  • GKOS 2015
  • NEA N/A
  • Fundamental
  • Price
  • GKOS $82.38
  • NEA $11.33
  • Analyst Decision
  • GKOS Strong Buy
  • NEA
  • Analyst Count
  • GKOS 12
  • NEA 0
  • Target Price
  • GKOS $128.58
  • NEA N/A
  • AVG Volume (30 Days)
  • GKOS 698.2K
  • NEA 803.4K
  • Earning Date
  • GKOS 11-03-2025
  • NEA 01-01-0001
  • Dividend Yield
  • GKOS N/A
  • NEA 4.23%
  • EPS Growth
  • GKOS N/A
  • NEA N/A
  • EPS
  • GKOS N/A
  • NEA N/A
  • Revenue
  • GKOS $432,953,000.00
  • NEA N/A
  • Revenue This Year
  • GKOS $28.79
  • NEA N/A
  • Revenue Next Year
  • GKOS $25.65
  • NEA N/A
  • P/E Ratio
  • GKOS N/A
  • NEA N/A
  • Revenue Growth
  • GKOS 26.70
  • NEA N/A
  • 52 Week Low
  • GKOS $77.10
  • NEA $9.20
  • 52 Week High
  • GKOS $163.71
  • NEA $11.37
  • Technical
  • Relative Strength Index (RSI)
  • GKOS 35.40
  • NEA 65.20
  • Support Level
  • GKOS $80.52
  • NEA $10.92
  • Resistance Level
  • GKOS $95.32
  • NEA $11.46
  • Average True Range (ATR)
  • GKOS 2.82
  • NEA 0.08
  • MACD
  • GKOS -1.23
  • NEA 0.03
  • Stochastic Oscillator
  • GKOS 11.29
  • NEA 75.93

About GKOS Glaukos Corporation

Glaukos Corp is an ophthalmic pharmaceutical and medical technology company focused on developing novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders, and retinal diseases. It has commenced commercialization activities for iDose TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical implant designed to continuously deliver glaucoma drug therapy inside the eye for extended periods of time. The company also offer commercially a proprietary bio-activated pharmaceutical therapy for the treatment of a rare corneal disorder, keratoconus. It has three primary commercialized micro-scale surgical device products designed to treat glaucoma: the iStent, the iStent inject W, and the iStent infinite.

About NEA Nuveen AMT-Free Quality Municipal Income Fund of Beneficial Interest Par Value $.01

Nuveen AMT-Free Municipal Income Fund is a diversified closed-end management investment company. Its investment objective is to provide current income exempt from regular federal income tax and the alternative minimum tax applicable to individuals, by investing in an actively managed portfolio of tax-exempt municipal securities. The company invest in Transportation, Utilities, Healthcare, Education and Civics, and other sectors, with maximum investment in Transportation.

Share on Social Networks: